Abbott Laboratories Long Term Debt

Abbott Laboratories (ABT) currently reports a long-term debt of $30B as of June 2026. That compares with $13B in the prior-year period — up 128.9% year over year. Use the charts on this page to explore Abbott Laboratories's long-term debt history and peer comparisons.

Abbott Laboratories's long-term debt increased from $13B to $30B — a 128.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abbott Laboratories reported $30B in long-term debt as of June 2026. That compares with $13B in the prior-year period — up 128.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $30B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abbott Laboratories, and consider following ABT for alerts when major investors trade the stock.

Abbott Laboratories is classified in the Healthcare sector. On long-term debt, it currently shows $30B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABT with unrelated industries.